圣诺生物：子公司维培那肽原料药上市申请获批

Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117), has received approval from the National Medical Products Administration for the marketing application of its active pharmaceutical ingredient, Vepagliflozin, which is a PEGylated form of Exenatide, aimed at treating type 2 diabetes and obesity [1] Group 1 - Shengnuo Biopharmaceutical's subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has recently received a marketing approval notification for Vepagliflozin [1] - Vepagliflozin acts as a GLP-1 receptor agonist, mimicking the physiological effects of natural GLP-1 by enhancing insulin secretion in a glucose-dependent manner [1] - The drug is intended for the treatment of type 2 diabetes and obesity, indicating its potential market relevance in addressing these health issues [1]